A detailed history of Soleus Capital Management, L.P. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 3,901,314 shares of BCAB stock, worth $8.04 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
3,901,314
Previous 4,065,197 4.03%
Holding current value
$8.04 Million
Previous $14 Million 61.78%
% of portfolio
0.54%
Previous 1.14%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.37 - $3.92 $224,519 - $642,421
-163,883 Reduced 4.03%
3,901,314 $5.34 Million
Q4 2023

Feb 14, 2024

SELL
$1.27 - $3.18 $369,570 - $925,380
-291,000 Reduced 6.68%
4,065,197 $10 Million
Q3 2023

Nov 14, 2023

BUY
$1.7 - $3.07 $59,500 - $107,450
35,000 Added 0.81%
4,356,197 $7.41 Million
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $231,839 - $831,600
100,800 Added 2.39%
4,321,197 $11.6 Million
Q4 2022

Feb 14, 2023

BUY
$6.29 - $11.01 $5.16 Million - $9.03 Million
819,894 Added 24.11%
4,220,397 $34.8 Million
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $405,132 - $1.64 Million
137,800 Added 4.22%
3,400,503 $26.2 Million
Q2 2022

Aug 15, 2022

BUY
$2.13 - $5.38 $1.59 Million - $4.02 Million
747,279 Added 29.71%
3,262,703 $9.3 Million
Q3 2021

Nov 15, 2021

SELL
$29.44 - $43.74 $8.21 Million - $12.2 Million
-278,809 Reduced 9.98%
2,515,424 $74.1 Million
Q2 2021

Aug 16, 2021

SELL
$38.07 - $56.17 $14.7 Million - $21.6 Million
-385,129 Reduced 12.11%
2,794,233 $118 Million
Q4 2020

Apr 29, 2021

BUY
$31.02 - $35.16 $65.9 Million - $74.7 Million
2,123,805 Added 201.2%
3,179,362 $0
Q4 2020

Feb 16, 2021

BUY
$31.02 - $35.16 $32.7 Million - $37.1 Million
1,055,557 New
1,055,557 $35.9 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $74.8M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.